ℹ️ Compiled from public regulatory records · Last regulator revision: April 8, 2026🚩 Report this page
Ferrous Asparto Glycinate
Active ingredient
Sold as Chromagen
US FDA
- Drug class
- -
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
- FDA reports (12 mo)
- 8
Overview
Ferrous Asparto Glycinate is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | April 8, 2026 |
USUnited States· FDA
1 product
Uses
INDICATIONS:
Chromagen™ is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency.
How to take
Sources & citations
- [1]FDA DailyMed · 13c5ed58-6333-49… · revised April 8, 2026 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.